Evidence map›Paper›PMID 24554104›Full record

Observational studyJournal of neurology, neurosurgery, and psychiatry2014

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Joachim Burman, Ellen Iacobaeus, Anders Svenningsson, Jan Lycke, Martin Gunnarsson, Petra Nilsson, Magnus Vrethem, Sten Fredrikson, Claes Martin, Anna Sandstedt and 7 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, neurosurgery, and psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Pooled it
  3. Trial
  4. Manufacture of Autologous CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Joachim BurmanDepartment of Neuroscience, Uppsala University, Uppsala, Sweden Department of Neurology, Uppsala University Hospital, Uppsala, Sweden.
Ellen IacobaeusNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institute Solna, Center for Molecular Medicine, Stockholm, Sweden.
Anders SvenningssonDepartment of Pharmacology and Clinical Neuroscience, Umeå University and University Hospital of Northern Sweden, Umeå, Sweden.
Jan LyckeDepartment of Neurology, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Martin GunnarssonDepartment of Neurology, Örebro University Hospital, Örebro, Sweden School of Health and Medical Sciences, Örebro University, Örebro, Sweden.
Petra NilssonDepartment of Neurology, Skåne University Hospital Lund, Lund, Sweden.
Magnus VrethemNeurology and Clinical Neurophysiology, Faculty of Health Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden Department of Neurology and Neurophysiology, County Council of Östergötland, Linköping, Sweden.
Sten FredriksonDepartment of Clinical Neuroscience, Karolinska Institute Huddinge, Stockholm, Sweden.
Claes MartinNeurology Unit, Division of Internal Medicine, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Anna SandstedtDepartment of Hematology, Linköping University Hospital, Linköping, Sweden.
Bertil UgglaSchool of Health and Medical Sciences, Örebro University, Örebro, Sweden Division of Hematology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Stig LenhoffDepartment of Hematology and Coagulation, Skåne University Hospital, Lund, Sweden.
Jan-Erik JohanssonDepartment of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.
Cecilia IsakssonDepartment of Radiosciences, Umeå University, Umeå, Sweden.
Hans HägglundDivision of Hematology, Department of Medical Science, Uppsala University Hospital, Uppsala, Sweden.
Kristina CarlsonDivision of Hematology, Department of Medical Science, Uppsala University Hospital, Uppsala, Sweden.
Jan FagiusDepartment of Neuroscience, Uppsala University, Uppsala, Sweden Department of Neurology, Uppsala University Hospital, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS.

methodsNeurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months.

resultsAt 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%).

conclusionsHSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.

Indexed as

AdolescentAdultBrainChildDisability EvaluationDisease-Free SurvivalFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisNeuroimagingRecurrenceMultiple Sclerosis

Identifiers

PMID24554104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.